VPH Stock Overview
A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Valeo Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.40 |
| 52 Week Low | CA$0.06 |
| Beta | 2.56 |
| 1 Month Change | 4.76% |
| 3 Month Change | -40.54% |
| 1 Year Change | -71.43% |
| 3 Year Change | -87.50% |
| 5 Year Change | -80.36% |
| Change since IPO | -83.08% |
Recent News & Updates
Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost
Jun 14
Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower
Apr 20Recent updates
Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost
Jun 14Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower
Apr 20Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing
Mar 02Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump
Jan 17Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%
Jun 08Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%
Jun 24Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts
Jun 17Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?
Feb 08Announcing: Valeo Pharma (CSE:VPH) Stock Increased An Energizing 208% In The Last Year
Dec 17
Shareholder Returns
| VPH | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 22.2% | -7.8% | -2.3% |
| 1Y | -71.4% | 30.5% | 8.2% |
Return vs Industry: VPH underperformed the Canadian Pharmaceuticals industry which returned 30.5% over the past year.
Return vs Market: VPH underperformed the Canadian Market which returned 8.2% over the past year.
Price Volatility
| VPH volatility | |
|---|---|
| VPH Average Weekly Movement | 23.7% |
| Pharmaceuticals Industry Average Movement | 13.4% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.0% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: VPH's share price has been volatile over the past 3 months.
Volatility Over Time: VPH's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 100 | Steve Saviuk | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
| VPH fundamental statistics | |
|---|---|
| Market cap | CA$10.85m |
| Earnings (TTM) | -CA$29.77m |
| Revenue (TTM) | CA$54.86m |
0.2x
P/S Ratio-0.4x
P/E RatioIs VPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPH income statement (TTM) | |
|---|---|
| Revenue | CA$54.86m |
| Cost of Revenue | CA$42.97m |
| Gross Profit | CA$11.89m |
| Other Expenses | CA$41.65m |
| Earnings | -CA$29.77m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 21.67% |
| Net Profit Margin | -54.26% |
| Debt/Equity Ratio | -121.8% |
How did VPH perform over the long term?
See historical performance and comparison